Statins for primary cardiovascular disease prevention among people with HIV: emergent directions.

ABSTRACT:

Purpose of review

While people with HIV (PWH) are living longer due to advances in antiretroviral therapy, recent data have demonstrated an increased risk of cardiovascular disease (CVD) among this population. This increased risk is thought to be due to both traditional (for example, smoking, diabetes) and HIV-specific (for example, inflammation, persistent immune activation) risk factors. This review focuses on the potential for statin therapy to mitigate this increased risk.

Recent findings

Several randomized clinical trials have demonstrated that statins, a class of lipid-lowering medications, are effective as a primary CVD prevention strategy among people without HIV. Among PWH, statins have been shown to lower cholesterol, exert immunomodulatory effects, stabilize coron

SUBMITTER: Fitch KV 

PROVIDER: S-EPMC9415230 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature